E1/E2/E3 Enzyme

E1 activating enzyme; E2 conjugating enzyme; E3 ligating enzyme; Ubiquitin activating enzyme; Ubiquitin conjugating enzyme; Ubiquitin ligase

Ubiquitin (UB) is a protein modifier that regulates many essential cellular processes. To initiate protein modification by UB, the E1 enzyme activates the C-terminal carboxylate of UB to launch its transfer through the E1-E2-E3 cascade onto target proteins. The E1 enzyme is the activating enzyme, to which ubiquitin is attached in an ATP-dependent reaction by a thioester bond. The E2 enzyme is the conjugating enzyme, to which the ubiquitin is transferred from the E1. The E3 is the ubiquitin ligase, which directly or indirectly catalyzes the transfer of the ubiquitin to the target protein (the substrate), with the formation of an isopeptide bond.

2-D08

Cat. No.: HY-114166

2-D08 is a cell permeable, mechanistically unique inhibitor of protein **SUMOylation**. 2-D08 also inhibits **Axl** with an IC_{50} of 0.49 nM.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AMG 232

Cat. No.: HY-12296

AMG 232 is a potent, selective and orally available inhibitor of **p53-MDM2** interaction, with an IC_{50} of 0.6 nM. AMG 232 binds to MDM2 with a K_d of 0.045 nM.



Purity: 99.90%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

APG-115

(AA-115)

Cat. No.: HY-101518

APG-115 (AA-115) is an orally active **MDM2** protein inhibitor binding to MDM2 protein with IC_{50} and K_i values of 3.8 nM and 1 nM, respectively. APG-115 blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and **apoptosis** in a p53-dependent manner.



Purity: 98.16%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

Avadomide

(CC 122)

Cat. No.: HY-100507

Avadomide (CC 122) is an orally active **cereblon** modulator. Avadomide modulates cereblon E3 ligase activity and induces **apoptosis** of diffuse large B-cell lymphoma (DLBCL) cell lines. Avadomide exhibits potent antitumor and immunomodulatory activities.



Purity: 99.53%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BH3I-1

(BHI1; BH 3I1)

Cat. No.: HY-100383

BH3I-1 is a **Bcl-2 family** antagonist, which inhibits the binding of the **Bak** BH3 peptide to **Bcl-xL** with a K_i of 2.4±0.2 μM in FP assay. BH3I-1 has a K_d of 5.3 μM against the **p53/MDM2** pair.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BI8622

Cat. No.: HY-120929

BI8622 is a specific inhibitor of the ubiquitin ligase **HUWE1** with an IC_{50} of 3.1 μM.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BI8626

Cat. No.: HY-120204

BI8626 is a specific inhibitor of the ubiquitin ligase **HUWE1** with an IC_{50} of 0.9 μM.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BRD5529

Cat. No.: HY-115497

BRD5529 is a selective **CARD9-E3 ubiquitin ligase TRIM62** protein-protein interaction inhibitor with an IC_{50} of 8.6 μM.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

C25-140

Cat. No.: HY-120934

C25-140, a first-in-class, orally active, and fairly selective **TRAF6-Ubc13** inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces **NF-κB** activation, and combats autoimmunity.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CC-92480

Cat. No.: HY-129395

CC-92480 is a cereblon E3 ubiquitin ligase modulating drug (CELMoD). CC-92480 shows high affinity to cereblon, resulting in potent antimyeloma activity.



Purity: 98.02%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

CC0651

Cat. No.: HY-15301

CC0651 is an allosteric inhibitor of the human **Cdc34 ubiquitin-conjugating enzyme**. CC0651 potently (IC_{50}=1.72 μM) inhibits the ubiquitination of $p27^{Kip1}$, as confirmed by dose-response analysis.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

COH000

Cat. No.: HY-114304

COH000 is an allosteric, covalent and irreversible inhibitor of **ubiquitin-like 1-activating enzyme (SUMO-activating enzyme) (E1)**, with an IC_{50} of 0.2 μM for SUMOylation in vitro.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CTX1

Cat. No.: HY-U00442

CTX1 is a **p53** activator that overcomes HdmX-mediated p53 repression. CTX1 exhibits potent anti-cancer activity in a mouse acute myeloid leukemia (AML) model system.



Purity: >96.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

DKM 2-93

Cat. No.: HY-101836

DKM 2-93 is a relatively selective inhibitor of **UBA5** with an IC_{50} of 430 μM.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Ginkgolic Acid (Ginkgolic acid (15:1); Ginkgolic acid I; Romanicardic acid)

Cat. No.: HY-N0077

Ginkgolic Acid is a natural compound that inhibits **SUMOylation** with an IC_{50} of 3.0 μM in in vitro assay.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GS143

Cat. No.: HY-110261

GS143 is a selec-tive **IκBα ubiquitination** inhibitor with an IC_{50} of 5.2 μM for $SCF^{\beta TrCP1}$-mediated **IκBα ubiquitylation**. GS143 sup-presses **NF-κB** acti-va-tion and tran-scrip-tion of tar-get genes and does not inhibit proteasome activity. GS143 has anti-asthma effect.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Hinokiflavone

Cat. No.: HY-N2360

Hinokiflavone is a novel modulator of **pre-mRNA** splicing activity in vitro and in cellulo. Hinokiflavone blocks splicing of pre-mRNA substrates by inhibiting spliceosome assembly, specifically preventing B complex formation.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Idasanutlin (RG7388)

Cat. No.: HY-15676

Idasanutlin (RG7388) is a potent and selective **MDM2** antagonist, inhibiting p53-MDM2 binding, with an IC_{50} of 6 nM.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Indole-3-carbinol (I3C; 3-Indolemethanol)

Cat. No.: HY-N0170

Indole-3-carbinol (I3C) inhibits **NF-κB** activity and also is an **Aryl hydrocarbon receptor** (**AhR**) agonist, and an inhibitor of **WWP1** (WW domain-containing ubiquitin E3 ligase 1).



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 200 mg, 1 g

LS-102

Cat. No.: HY-135844

LS-102 is a selective E3 ubiquitin ligase **synoviolin (Syvn1)** inhibitor. LS-102 inhibits the autoubiquitination of synoviolin with an IC_{50} of 35 μM. LS-102 has the potential for rheumatoid arthritis treatment.



Purity: 96.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MD-224

Cat. No.: HY-114312

MD-224 is a first-in-class and highly potent small-molecule human murine double minute 2 (**MDM2**) degrader based on the proteolysistargeting chimera (PROTAC) concept.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MI-1061

Cat. No.: HY-125858

MI-1061 is a potent, orally bioavailable, and chemically stable **MDM2** (MDM2-p53 interaction) inhibitor (IC_{50}=4.4 nM; K_i=0.16 nM). MI-1061 potently activates **p53**, induces **apoptosis**, and has anti-tumor activity.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

MI-773

Cat. No.: HY-17493

MI-773 is a new small molecule inhibitor of the **MDM2-p53** interaction, binds to **MDM2** with high affinity (K_i=0.88 nM) and blocks the p53-MDM2 interaction.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Milademetan

(DS-3032)

Cat. No.: HY-101266

Milademetan (DS-3032) is a specific and orally active **MDM2** inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces **G1 cell cycle arrest**, senescence and **apoptosis**.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Milademetan tosylate hydrate

(DS-3032b; DS-3032 tosylate hydrate)

Cat. No.: HY-101266B

Milademetan (DS-3032) tosylate hydrate is a specific and orally active **MDM2** inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces **G1 cell cycle arrest**, senescence and **apoptosis**.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

ML-792

Cat. No.: HY-108702

ML-792 is a potent and selective inhibitor of **SAE/SUMO1** and **SAE/SUMO2** in enzymatic assays (IC_{50} values of 3 and 11 nM, respectively) compared with NAE/NEDD8 and UAE/ubiquitin (IC_{50} values of 32 μM and >100 μM, respectively).



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MX69

Cat. No.: HY-100892

MX69 is an inhibitor of **MDM2/XIAP**, used for cancer treatment.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

NAcM-OPT

Cat. No.: HY-111505

NAcM-OPT is an orally bioavailable cullin neddylation 1 (**DCN1**) inhibitor, which potently inhibits the **DCN1-UBE2M** interaction.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NSC232003

Cat. No.: HY-103236

NSC232003 is a highly potent and cell-permeable **UHRF1** inhibitor, which inhibits DNA methylation in vitro and disrupts DNMT1/UHRF1 interactions at a cellular level.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

NSC624206

Cat. No.: HY-103436

NSC624206 is an inhibitor of **ubiquitin E1 (UBA1)**, with an IC_{50} of ~9 μM. NSC624206 specifically blocks ubiquitin-thioester formation (IC_{50}=13 μM) but has no effect on ubiquitin adenylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC697923

Cat. No.: HY-13811

NSC697923 is a potent **UBE2N** (ubiquitin-conjugating enzyme E2 N, Ubc13) inhibitor. NSC697923 induces neuroblastoma (NB) cell death via promoting nuclear importation of p53 in p53 wild-type NB cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nutlin-3

Cat. No.: HY-50696

Nutlin-3 is a commercial available **p53-MDM2** inhibitor, with K_i of 90 nM.



relative stereochemistry

Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nutlin-3a

Cat. No.: HY-10029

Nutlin-3a, an active enantiomer of Nutlin-3, is a potent **murine double minute (MDM2)** inhibitor (IC_{50}=90 nM). Nutlin-3a inhibits **MDM2-p53** interactions and stabilizes the p53 protein, and induces cell **autophagy** and **apoptosis**.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Nutlin-3b

Cat. No.: HY-15335

Nutlin-3b is a **p53/MDM2** inhibitor with an IC_{50} of 13.6 μM. Nutlin-3b is 150 times less potent in binding to MDM2 than Nutlin-3a.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NVP-CGM097

(CGM097)

Cat. No.: HY-15954

NVP-CGM097 is a potent and selective **MDM2** inhibitor with IC_{50} of 1.7±0.1 nM for **hMDM2**.



Purity: 98.32%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

NVP-CGM097 sulfate

(CGM097 sulfate)

Cat. No.: HY-15954B

NVP-CGM097 sulfate is a potent and selective **MDM2** inhibitor with IC_{50} of 1.7±0.1 nM for **hMDM2**.



Purity: 98.76%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

p53 and MDM2 proteins-interaction-inhibitor (chiral)

Cat. No.: HY-70027

p53 and MDM2 proteins-interaction-inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins.



Purity: 97.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

p53 and MDM2 proteins-interaction-inhibitor dihydrochloride

Cat. No.: HY-70027A

p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is an inhibitor of the interaction between p53 and MDM2 proteins.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 100 mg

PROTAC MDM2 Degrader-1

Cat. No.: HY-128840

PROTAC MDM2 Degrader-1 is a **MDM2** degrader based on **PROTAC** technology. PROTAC MDM2 Degrader-1 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

PROTAC MDM2 Degrader-2

Cat. No.: HY-128841

PROTAC MDM2 Degrader-2 is a **MDM2** degrader based on **PROTAC** technology. PROTAC MDM2 Degrader-2 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

PROTAC MDM2 Degrader-3

Cat. No.: HY-128842

PROTAC MDM2 Degrader-3 is a **MDM2** degrader based on **PROTAC** technology. PROTAC MDM2 Degrader-3 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.



Purity: 98.69%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PRT4165

(NSC600157)

Cat. No.: HY-19817

PRT4165 is a potent inhibitor of **PRC1-mediated H2A ubiquitylation**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PYR-41

Cat. No.: HY-13296

PYR-41 is a selective and cell permeable inhibitor of ubiquitin-activating enzyme **E1** with an IC_{50} of < 10 μM, with little activity at E2 and E3.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PYZD-4409

Cat. No.: HY-13297

PYZD-4409 is a specific inhibitor of the **ubiquitin-activating enzyme UBA1** with an IC_{50} of 20 μM (cell-free enzymatic assay). PYZD-4409 induces cell death in malignant cells and preferentially inhibits the clonogenic growth of primary acute myeloid leukemia cells.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RG7112

(RO5045337)

Cat. No.: HY-10959

RG7112 is a potent, selective, first clinical, orally active and blood-brain barrier crossed **MDM2-p53** inhibitor, with an IC_{50} of 18 nM and a K_D of 11 nM for binding to MDM2.



Purity: 99.91%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RO8994

Cat. No.: HY-16999

RO8994 is a highly potent and selective series of spiroindolinone small-molecule MDM2 inhibitor, with IC50 of 5 nM (HTRF binding assays) and 20 nM (MTT proliferation assays).



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SAR405838

(MI-77301)

Cat. No.: HY-18986

SAR405838 is a highly potent and selective MDM2 inhibitor, binds to MDM2 with Ki= 0.88 nM and has high specificity over other proteins.



Purity: 95.14%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Serdemetan

(JNJ-26854165)

Cat. No.: HY-12025

Serdemetan(JNJ-26854165) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53.



Purity: 99.23%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Siremadlin

(NVP-HDM201; HDM201)

Cat. No.: HY-18658

Siremadlin (NVP-HDM201) is a potent, orally bioavailable and highly specific **p53-MDM2** interaction inhibitor.



Purity: 99.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SJ-172550

Cat. No.: HY-16664

SJ-172550 is a small molecule inhibitor of **MDMX**; competes for the wild type p53 peptide binding to MDMX with an EC_{50} of 5 μM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Skp2 Inhibitor C1

(SKPin C1)

Cat. No.: HY-16661

Skp2 Inhibitor C1(SKPin C1) is a specific small molecule inhibitor of Skp2-mediated p27 degradation, selectively inhibited Skp2-mediated p27 degradation by reducing p27 binding through key compound-receptor contacts.



Purity: 96.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SMIP004

Cat. No.: HY-15694

SMIP004 is a **SKP2 E3 ligase** inhibitor, which downregulates SKP2 and to stabilise p27. SMIP004 is a cancer cell selective **apoptosis** inducer of human prostate cancer cells.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Solasodine

(Purapuridine; Solancarpidine; Solasodin)

Cat. No.: HY-N0068

Solasodine(Purapuridine) is a poisonous alkaloid chemical compound that occurs in plants of the Solanaceae family. Solasodine showed selective cytotoxicity against cervical cancer cell line (HeLa) and human myeloid leukemia cell line (U937).



Purity: 98.86%
Clinical Data: No Development Reported
Size: 100 mg

SZL P1-41

Cat. No.: HY-100237

SZL P1-41 is a specific **Skp2** inhibitor, binds to the F-box domain of Skp2 to prevent Skp1 association and Skp2 SCF complex formation. SZL P1-41, like Skp2 deficiency, augments p27-mediated apoptosis/senescence, while it impairs Akt-driven glycolysis. Anti-tumor activities.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAK-243

(MLN7243)

Cat. No.: HY-100487

TAK-243 (MLN7243) is a first-in-class, selective ubiquitin activating enzyme, **UAE (UBA1)** inhibitor (IC_{50}=1 nM), which blocks ubiquitin conjugation, disrupting monoubiquitin signaling as well as global protein ubiquitination.



Purity: 99.43%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAK-981

Cat. No.: HY-111789

TAK-981 is a first in class and selective inhibitor of the **SUMOylation** enzymatic cascade, with potential immune-activating and antineoplastic activities.



Purity: 98.56%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TZ9

Cat. No.: HY-18643

TZ9 is a novel inhibitor of Rad6 ubiquitin conjugating enzyme(E2 enzyme); inhibits MDA-MB-231 cell proliferation with IC50 of ~6 uM.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

VII-31

Cat. No.: HY-133558

VII-31 is a potent **NEDDylation** pathway activator to inhibit the tumor progression in vitro and in vivo. VII-31 induces **apoptosis** via intrinsic and extrinsic pathways.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WS-383

Cat. No.: HY-126075A

WS-383 is a potent, selective and reversible inhibitor of **DCN1-UBC12** interaction, with an IC_{50} of 11 nM. WS-383 inhibits Cul3/1 neddylation, induces accumulation of p21, p27 and NRF2.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

YH239-EE

Cat. No.: HY-12287

YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent. IC50 value: Target: MDM2/p53 YH239-EE inhibits the growth of OCI-AML-3 cells with wild type p53 by inhibiting the p53-MDM2 interaction.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg